English
繁體中文
ALL
2022
2021
2020~2015
Dec 08, 2022
SyneuRx CEO Emil Tsai Named Fellow of National Academy of Inventors
July 31, 2022
SyneuRx Announces Final Results of Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)
July 25, 2022
Dr. Joseph T. Coyle Named Chair of SyneuRx’s Scientific Advisory Board
Apr 13, 2022
SyneuRx Reaches Target Enrollment in Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)
Jan 06, 2022
SyneuRx Announces Oral COVID-19 Antiviral Drug Candidate Pentarlandir® Is Showing Effectiveness Against Both the Omicron and Delta COVID-19 Variants
